Literature DB >> 31149117

BEHAVIOUR OF EARLY THYROGLOBULIN AFTER TOTAL THYROIDECTOMY FOR DIFFERENTIATED THYROID CANCER.

D Pérez1, M Marulanda1, A Sanabria1.   

Abstract

CONTEXT: The objectives of treatment of thyroid carcinoma include hormonal suppression, radioiodine ablation and follow-up with serum thyroglobulin (Tg). Tg levels should not be measured before six weeks post-thyroidectomy.
OBJECTIVE: To describe the behaviour of early postoperative Tg in patients who underwent total thyroidectomy and its ability to predict the serum Tg levels after suppression.
DESIGN: This is a retrospective cohort study. SUBJECTS AND METHODS: Adult patients who underwent total thyroidectomy with at least two postoperative measurements of serum Tg, negative TgAb and concomitant serum TSH values were included. Tg, TgAb and TSH level measurements were completed two weeks postoperatively and during the follow-up period.
RESULTS: Twenty-nine patients fulfilled all criteria. The median serum Tg level at two weeks after surgery was 3.8 ug/L (0.3 -300) with a serum TSH level of 69.9 mU/L; 11-227. At the two-week measurement, 16 (55%) patients had serum Tg levels lower than 5 ug/L and 4 patients had levels between 5-10 µg/L.
CONCLUSIONS: Postoperative early serum Tg could be an alternative to values measured six months after surgery and could be used as a predictive tool to make earlier therapeutic decisions.

Entities:  

Keywords:  follow-up; radioiodine ablation; thyroglobulin; well differentiated thyroid carcinoma

Year:  2016        PMID: 31149117      PMCID: PMC6535275          DOI: 10.4183/aeb.2016.370

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  22 in total

1.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

Review 2.  Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.

Authors:  C Nascimento; I Borget; A Al Ghuzlan; D Deandreis; L Chami; J P Travagli; D Hartl; J Lumbroso; C Chougnet; L Lacroix; E Baudin; M Schlumberger; S Leboulleux
Journal:  Endocr Relat Cancer       Date:  2011-03-03       Impact factor: 5.678

3.  Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.

Authors:  Karen A Heemstra; Ying Y Liu; Marcel Stokkel; Job Kievit; Eleonora Corssmit; Alberto M Pereira; Johannes A Romijn; Johannes W A Smit
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

Review 4.  Risk-adapted management of thyroid cancer.

Authors:  R Michael Tuttle
Journal:  Endocr Pract       Date:  2008-09       Impact factor: 3.443

5.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

6.  Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.

Authors:  Jandee Lee; Mee Jin Yun; Kee Hyun Nam; Woong Youn Chung; Euy-Young Soh; Cheong Soo Park
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

7.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence.

Authors:  Pedro Weslley Rosario; Arthur Cezar Malard Xavier; Maria Regina Calsolari
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

8.  Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Luca Ceriani; Marco Maffioli
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

9.  Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Marco Maffioli; Luca Ceriani; Diego De Palma; Giuseppe Spriano
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

10.  Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis.

Authors:  C F A Eustatia-Rutten; J W A Smit; J A Romijn; E P M van der Kleij-Corssmit; A M Pereira; M P Stokkel; J Kievit
Journal:  Clin Endocrinol (Oxf)       Date:  2004-07       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.